Discover

DNTH
Dianthus Therapeutics, Inc.
90.21
2 x 69.61
2 x 115.58
bid
ask
-
7.27
7.46%
2 @ 07:11 AM
89.15 -1.06 (1.18%)
Ytd118.90%
1y402.28%
90.08
day range
97.55
17.88
52 week range
98.70
Open96.68Prev Close97.48Low90.08High97.55Mkt Cap4.93B
Vol1.61MAvg Vol900.76KEPS-4.23P/EN/AForward P/E-19.40
Beta0.07Short Ratio7.33Inst. Own120.45%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0550-d Avg86.71200-d Avg59.861yr Est127.67

DNTH News

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
globenewswire.com
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized My

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate cla

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
benzinga.com
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's rilipr

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says
benzinga.com
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

benzinga.com
Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the an

benzinga.com
Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price T

Wolfe Research analyst Andy Chen initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
benzinga.com
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

benzinga.com
Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Targ

Wells Fargo analyst Sadia Rahman initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $103

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
benzinga.com
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about th

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $80

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

benzinga.com
Raymond James Upgrades Dianthus Therapeutics to Strong Buy, Raises Price Target to $123

Raymond James analyst Steven Seedhouse upgrades Dianthus Therapeutics (NASDAQ:DNTH) from Outperfo

benzinga.com
Baird Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $132

Baird analyst Joel Beatty maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and rai

benzinga.com
Clear Street Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130

Clear Street analyst Bill Maughan maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and ra

benzinga.com
Dianthus Therapeutics Announces Proposed $400M Public Offering

Dianthus announced that it has commenced an underwritten public offering of $400 million of shares o

benzinga.com
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $130

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

benzinga.com
Oppenheimer Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $145

Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperfo

Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Highe

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
benzinga.com
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism

Dianthus Therapeutics shares jump after early success in a Phase 3 trial for CIDP treatment clasepru

benzinga.com
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $110

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Dianthus Therapeutics Earnings Review: Q4 Summary
benzinga.com
Dianthus Therapeutics Earnings Review: Q4 Summary

benzinga.com
Dianthus Therapeutics Q4 EPS $(1.43) Misses $(1.02) Estimate, Sales $284.000K Miss $398.917K Estimat

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(1.43) per share which missed the

benzinga.com
Dianthus Therapeutics Announces An Early GO Decision Based On An Interim Responder Analysis In The P

Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responder

Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday

Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) ga

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
benzinga.com
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views

benzinga.com
Guggenheim Maintains Buy on Dianthus Therapeutics, Raises Price Target to $200

Guggenheim analyst Yatin Suneja maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and rais

What 4 Analyst Ratings Have To Say About Dianthus Therapeutics
benzinga.com
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $55

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

benzinga.com
Jefferies Maintains Buy on Dianthus Therapeutics, Raises Price Target to $81

Jefferies analyst Maury Raycroft maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and rai

benzinga.com
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $63

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

benzinga.com
Wedbush Reiterates Outperform on Dianthus Therapeutics, Maintains $46 Price Target

Wedbush analyst Laura Chico reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and

The Insider Report: Prepare for the Next Dip Buying Opportunity
benzinga.com
The Insider Report: Prepare for the Next Dip Buying Opportunity

benzinga.com
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $47

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $46

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

benzinga.com
Dianthus Therapeutics Reviews New Data From Phase 2 MaGic Trial Of Claseprubart In Generalized Myast

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis,

benzinga.com
Dianthus Therapeutics Signs Exclusive License Deal With Leads Biolabs For DNTH212, A Phase 1 Ready B

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce

benzinga.com
Truist Securities Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Targe

Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH

benzinga.com
Clear Street Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of

Clear Street analyst Bill Maughan initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with

benzinga.com
Stifel Maintains Buy on Dianthus Therapeutics, Raises Price Target to $65

Stifel analyst Alex Thompson maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
benzinga.com
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday

benzinga.com
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $44

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
benzinga.com
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ran

benzinga.com
Raymond James Reiterates Outperform on Dianthus Therapeutics, Raises Price Target to $63

Raymond James analyst Steven Seedhouse reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Outp

benzinga.com
Analyst Expectations For Dianthus Therapeutics's Future

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In